1 Study Matches
A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients with Hereditary Angioedema (HAE)
This study involves the use of a new medicine known as ISIS 721744 as a new treatment for Hereditary Angioedema, which is designed to lower the amount of a protein, known as prekallikrein (PKK), which is made by your liver. When PKK is made by the liver and released into your blood stream, it can lead to Hereditary Angioedema attacks. Therefore, the purpose of this study is to assess if reducing the amount of PKK can reduce your HAE attacks and to see how safe ISIS 721744 is for patients with HAE.
There will be 11 in-person visits over 11 months that you will need to come to where there will be blood drawn, as well as other assesments. You will receive and injection of the study drug once a month.
Hunter Smith - at firstname.lastname@example.org
Inclusion Criteria:Must be 12 years of age or older
Must have a documented diagnosis of Hereditary Angioedema Type 1 or 2
Experience a minimum of 2 attacks during the screening period
Females must refrain from becoming pregnant for the duration of the study
Exclusion Criteria:Diagnosis of any other type of angioedema
Infectious Diseases & Immune System, Allergies